Market Intelligence, Clinical Progress, and High-Purity Reagents for Cartilage Disorders and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ITGA10 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ITGA10 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin controlled (<1 EU/μg). Sequence Verified. HEK293 expressed for native glycosylation. |
View ITGA10 Products |
| Gene Delivery | ITGA10 Promise-ORF / Lentivirus Full-length ORF for stable cell lines to support cell-based conformation assays. |
View ITGA10 Products |
| Benchmark Ab | Anti-ITGA10 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View ITGA10 Products |
| Validator | ITGA10 siRNA Set For knockdown verification and target specificity validation. |
View ITGA10 Products |
| Related Target A | ITGB1 (Integrin Beta 1) Obligate heterodimer partner; required for functional ITGA10/ITGB1 complex assembly. |
View ITGB1 Products |
| Related Target B | ITGA11 (Integrin Alpha 11) Closest sequence homolog; critical for off-target counter-screening. |
View ITGA11 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homology counter-screening (ITGA11 vs ITGA10) | Human ITGA11 and ITGA10 recombinant proteins strictly verified by mass spectrometry and purity >95%. |
| Conformation-dependent heterodimer validation | Lentivirus premade particles for ITGA10 and ITGB1 co-transduction to build stable heterodimer-expressing cell lines. |
| Lack of clinical reference controls | Sequence-verified benchmark antibodies synthesized with native IgG scaffolds. |
| False positives in binding assays | Sequence-verified siRNA pool included to confirm target-specific binding knockdown. |
Live ITGA10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ITGA10 therapeutics is intensifying, with major players shifting focus from traditional mesenchymal stem cell (MSC) markers to targeted Antibody-Drug Conjugates (ADCs) for oncology. As first-generation therapies for cartilage repair reach clinical evaluation, the next wave of R&D is targeting ITGA10-positive cancer stem cells in glioblastoma and soft tissue sarcomas.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Xintela AB | Glioblastoma, Triple-Negative Breast Cancer (TNBC) | Internalization Assay (Need high-purity, glycosylated ECD-Fc protein for screening) |
| Cell Therapy (MSC Marker) | Xintela (XSTEM) | Osteoarthritis, Cartilage Damage | Flow Cytometry Validation (Need Lentivirus for stable overexpression validation) |
| Monoclonal Antibody (mAb) | Preclinical consortia | Chondrosarcoma, Solid Tumors | Selectivity Assay (Need ITGA11 and other integrin family proteins for counter-screening) |